Bio-Path Holdings (Bio-Path Holdings) Short Percentage of Float

View and export this data going back to 2008. Start your Free Trial

What is Bio-Path Holdings Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Bio-Path Holdings's Short Percentage of Float

For the Biotechnology subindustry, Bio-Path Holdings's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Path Holdings's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's Short Percentage of Float falls into.

Bio-Path Holdings (Bio-Path Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Path Holdings Inc (NAS:BPTH) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

IBPB:Germany

Address

4710 Bellaire Boulevard, Suite 210, Bellaire, TX, USA, 77401

Website

https://www.biopathholdings.com

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.

Executives

Aline Sherwood	director	347 BRANDYWINE DRIVE, IRWIN PA 15642
Tamaro Martina Molsbergen	director	1307 SUMMERHILL DRIVE, MALVERN PA 19355
Mark P Colonnese	director	4674 ANDREA POINTE, MARIETTA GA 30062
Peter Henry Nielsen	director, officer: President, CEO & CFO	20651 PRINCE CREEK, KATY TX 77450
Paul Aubert	director	4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE TX 77401
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Heath Cleaver	director	4010 BALSAM FIR LN., SPRING TX 77386
Ulrich W. Mueller	officer: COO & Secretary	17841 6TH AVE NW, SHORELINE WA 98177
Amy Sing	director	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Michael J. Garrison	director	2626 SOUTH LOOP, SUITE 180, HOUSTON TX 77054
Douglas P Morris	director	550 MADISON AVENUE, SUITE 3206, NEW YORK NY 10022
Gillian C Ivers-read	director	C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Thomas E Garrison	director	P O BOX 150248, OGDEN UT 84415